

Curriculum Vitae

Angelo Paradiso MD – PhD - Scientific Director of NCI Bari (Italy)

Function within OECD - Co-opted Board Member, **Chairperson Educational Working Group**

Education

- **Degrees:** Medicine in 1980, University of Bari
- **Specialization:**
 - Oncology** in 1985, University of Bari,
 - Applied Pharmacology**, 1988, University of Bari

Professional Experience (function and hospital/University etc)

- from 2008 Scientific Director NCI Bari Giovanni Paolo II
- from 2005 Deputy Scientific Director
- from 2001 – Vice Scientific Director NCI Bari
- from 1999 – Director of the Experimental Clinical Oncology Laboratory, NCI Bari
- 1998-1999 Associate Director Experimental Clinical Oncology Laboratory, NCI Bari
- 1995-1998 Assistant Director Medical Oncology Division, NCI Bari
- 1988-1989 Post-Doc fellow Institute fur Strahlenbiologie, Munster University, Germany
- 1988-1994 Medical Assistent Div. Oncologia Medica, Laboratorio Oncologia Sperimentale, Osp. Oncologico di Bari
- 1985-1987 Triennial Fellowship A.I.R.C. c/o Div. Oncologia Medica, Ospedale Oncologico Bari
- 1983-1984 Post-Doc fellow INT Milano c/o Oncologia Sperimentale C

Special Recognition

- **Main areas of research interest:**
 - Study design and conduction;
 - Clinical controlled studies;
 - Prognostic predictive factors;
 - Quality Control;
 - Tissue Banks;
 - Networking
- **Teaching:**
 - Oncology in Medical Faculty of University of Bari
- **Awards:**
 - 1987 International Prize “Fiuggi city of Alabama University – USA”
 - 1988 National Prize “Giorgio Prodi” launched by A.I.O.M.
 - 1993 National Prize “Medicina FORUM National Academy”
- **Positions held in Cancer Organisation:**
 - National Co-ordinator of the INQAT (Italian Network for Quality Assesment of Tumor biomarkers, www.inqat.org)
 - Coordinator of “National Virtual Tumour Tissue Bank “ sponsored by Alleanza contro il Cancro (2004)
 - Member of the group Receptor Biomarker Study Group of the EORTC (Chairman M. Schmitt, Muenchen)
 -
 - Chairman of the Italia-China Bilateral Cohoperation Program for the development of an “Italia-China Virtual Tumour Tissue Bank”
 - Member of the National Committee Cancer
 - Member of the LILT National Committee “Alimentazione” from October 2007

• **Publications: 2008**

- 1:** Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwöpe I, Lukas A, Müller V, Milde-Langosch K, Nühlig J, Foekens J, Maier S, Schmitt M, Lesche R. Multicenter Study Using Paraffin-Embedded Tumor Tissue Testing PITX2 DNA Methylation As a Marker for Outcome Prediction in Tamoxifen-Treated, Node-Negative Breast Cancer Patients. *J Clin Oncol.* 2008 Aug 18. [Epub ahead of print]
- 2:** Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A. Molecular and in silico analysis of BRCA1 and BRCA2 variants. *Mutat Res.* 2008 Jul 18. [Epub ahead of print]
- 3:** Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. *Biochem Pharmacol.* 2008 Mar 1;75(5):1035-44. Epub 2007 Dec 3.
- 4:** Aresta A, Calvano CD, Palmisano F, Zambonin CG, Monaco A, Tommasi S, Pilato B, Paradiso A. Impact of sample preparation in peptide/protein profiling in human serum by MALDI-TOF mass spectrometry. *J Pharm Biomed Anal.* 2008 Jan 7;46(1):157-64. Epub 2007 Oct 16.
- 5:** Carpagnano GE, Foschino-Barbaro MP, Spanevello A, Resta O, Carpagnano F, Mulé G, Pinto R, Tommasi S, Paradiso A. 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer. *Am J Respir Crit Care Med.* 2008 Feb 1;177(3):337-41. Epub 2007 Oct 25.
- 6:** Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A. Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. *Bioorg Med Chem.* 2008 Jan 1;16(1):362-73. Epub 2007 Sep 25.
- 7:** Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, Palli D, Ottini L. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. *Breast Cancer Res Treat.* 2008 Jul;110(1):161-7. Epub 2007 Jul 28.
- 8:** Bellizzi A, Mangia A, Chiriatti A, Petroni S, Quaranta M, Schittulli F, Malfettone A, Cardone RA, Paradiso A, Reshkin SJ. RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease. *Int J Mol Med.* 2008 Jul;22(1):25-31.
- 9:** Saghatchian M, Hummel H, Otter R, de Valeriola D, Van Harten W, Paradiso A, Koot B, Ringborg U, Tursz T; Organisation of European Cancer Institutes. Towards quality, comprehensiveness and excellence. The accreditation project of the Organisation of European Cancer Institutes (OEI). *Tumori.* 2008 Mar-Apr;94(2):164-71.
- 10:** Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A. Molecular and in silico analysis of BRCA1 and BRCA2 variants. *Mutat Res.* 2008 Jul 18. [Epub ahead of print]
- 11:** Mangia A, Chiriatti A, Chiarappa P, Incalza MA, Antonaci G, Pilato B, Simone G, Tommasi S, Paradiso A. Touch imprint cytology in tumor tissue banks for the confirmation of neoplastic cellularity and for DNA extraction. *Arch Pathol Lab Med.* 2008 Jun;132(6):974-8.
- 12:** Sebastian S, Azzariti A, Accardi R, Conti D, Pilato B, LaCalamita R, Porcelli L, Simone GM, Tommasi S, Tommasino M, Paradiso A. Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. *Int J Mol Med.* 2008 Jun;21(6):809-17.
- 13:** Lacalamita R, Schirone M, Paradiso A. ISO 9001:2000 applied to a research oncology laboratory: which problems? The

experience of National Cancer Institute-Bari.

Ann Oncol. 2008 Jun;19(6):1207-8. Epub 2008 Apr 25. No abstract available.

14: Mangia A, Chiarappa P, Tommasi S, Chiriatti A, Petroni S, Schittulli F, Paradiso A.

Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers.

Cancer Genet Cytogenet. 2008 Apr 15;182(2):75-83.

15: Divella R, Lacalamita R, Tommasi S, Coviello M, Daniele A, Garrisi VM, Abbate I, Simone G, Gadaleta C, Paradiso A, Quaranta M.

PAI-1, t-PA and circulating hTERT DNA as related to virus infection in liver carcinogenesis.

Anticancer Res. 2008 Jan-Feb;28(1A):223-8.

16: Verderio P, Ramsden SC, Orlando C, Pizzamiglio S, Paradiso A, Neumaier M, Pazzagli M, Marubini E.

External quality assessment schemes for real-time PCR: a statistical procedure to corrective actions.

Clin Chem Lab Med. 2008 Mar 14. [Epub ahead of print]

17: Seymour IJ, Casadei S, Zampiga V, Rosato S, Danesi R, Falcini F, Strada M, Morini N, Naldoni C, Paradiso A, Tommasi S, Schittulli F, Amadori D, Calistri D.

Disease family history and modification of breast cancer risk in common BRCA2 variants.

Oncol Rep. 2008 Mar;19(3):783-6.

18: Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M Perrone R, Azzariti A, Simone GM, Paradiso A.

4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.

Bioorg Med Chem. 2008 Apr 1;16(7):3732-43.

19: Giannelli G, Sgarra C, Porcelli L, Azzariti A, Antonaci S, Paradiso A.

EGFR and VEGFR as potential target for biological therapies in HCC cells.

Cancer Lett. 2008 Apr 18;262(2):257-64.